Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

Presentation TCT 2021

Equipoise Is a Myth: NOACs Will Be Superior to LAAO

Presenter: Renato D. Lopes

November 06, 2021

Presentation TCT 2021

Featured Lecture: Clinical Outcomes of LAAO versus NOACS in Atrial Fibrillation in Patients with Prior Ischemic Stroke: Is There Room for Improvement in Clinical Outcomes?

Presenter: Jens Erik Nielsen-Kudsk

November 04, 2021

Presentation TCT 2019

LAA Closure vs. NOACs: Pros and Cons, PRAGUE 17, and Additional Trials

Presenter: Vivek Reddy

September 26, 2019

Presentation TCT 2018

Debate: Is LAA Closure a Valid Alternative for Patients With No or Mild Contraindications to Anticoagulants? No NOACs Are Strongly Preferred to LAA Closure!

Presenter: James B. Hermiller Jr, David Hildick-Smith, Freek W.A. Verheugt

September 24, 2018

News Conference News TCT 2017

Longer-term Outcomes of Watchman Reassure as Debate Continues Over How It Should Be Used

Todd Neale

November 02, 2017

Presentation TCT 2017

Amulet: Data Synthesis and Ongoing Trials

Presenter: William A. Gray, Vivek Y. Reddy, Fabian Nietlispach

October 30, 2017

Presentation TCT 2017

WATCHMAN: Data Synthesis and Ongoing Trials

Presenter: William A. Gray, Vivek Y. Reddy

October 30, 2017

Presentation TCT 2017

Do the PIONEER and RE-DUAL Results Alter LAA Closure Decisions?

Presenter: William A. Gray, Vivek Y. Reddy, C. Michael Gibson

October 30, 2017

Presentation TCT 2017

Should the Improved Results With NOACs Compared to Warfarin Change LAA Closure Decisions?

Presenter: William A. Gray, Vivek Y. Reddy, Kurt Huber

October 30, 2017

Presentation TCT 2017

Strengths and Limitations of VKA and NOACs in Clinical Practice

Presenter: Christopher B. Granger, Horst Sievert

October 30, 2017

Presentation TCT 2016

Pivotal Trial Design Considerations: Noninferiority vs Superiority, Device, Control Arm Anticoagulation Durations, NOAC Considerations and More Industry and Clinician Perspectives

Presenter: Aaron V. Kaplan, Rachel Neubrander, Brian K. Whisenant

November 01, 2016

Presentation TCT 2016

Debate: Is Left Atrial Appendage Closure Underutilized? No, NOACs Have the Best Efficacy and Safety Profile for Most Patients!

Presenter: Andreas Baumbach, David Hildick-Smith, Jai-Wun Park

November 01, 2016

Presentation TCT 2016

Debate #2: Is LAA Closure Preferred First-line Treatment in Patients With Recent Stents or ACS? No A Combination of Antiplatelet Agents and Warfarin/NOACs Shoud Be Tried First!

Presenter: David R. Holmes Jr., Josep Rodés-Cabau, Freek W.A. Verheugt

October 30, 2016

Presentation TCT 2016

Meta-analysis and Synthesis of Watchman Trials: Relative Safety and Efficacy vs Warfarin and NOACs in Anticoagulant Indicated Patients (Including Cost-effectiveness)

Presenter: Vivek Y. Reddy, Steven J. Yakubov

October 30, 2016

Presentation TCT 2016

What are Valid Absolute and Relative Contraindications to Warfarin and NOACs?

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt

October 30, 2016

Presentation TCT 2016

Warfarin and NOACS for Atrial Fibrillation: Efficacy, Complications, and Compliance

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Michelle O'Donoghue

October 30, 2016

Presentation TCT 2014

Bleeding and Stroke Risk Assessment in Atrial Fibrillation: Choosing between Warfarin, NOACS, Antiplatelets, or Nothing?

Presenter: Matthew J. Price, Michael D. Ezekowitz

September 15, 2014

Advertisement

Equipoise Is a Myth: NOACs Will Be Superior to LAAO

Featured Lecture: Clinical Outcomes of LAAO versus NOACS in Atrial Fibrillation in Patients with Prior Ischemic Stroke: Is There Room for Improvement in Clinical Outcomes?

LAA Closure vs. NOACs: Pros and Cons, PRAGUE 17, and Additional Trials

Debate: Is LAA Closure a Valid Alternative for Patients With No or Mild Contraindications to Anticoagulants? No NOACs Are Strongly Preferred to LAA Closure!

Longer-term Outcomes of Watchman Reassure as Debate Continues Over How It Should Be Used

Amulet: Data Synthesis and Ongoing Trials

WATCHMAN: Data Synthesis and Ongoing Trials

Do the PIONEER and RE-DUAL Results Alter LAA Closure Decisions?

Should the Improved Results With NOACs Compared to Warfarin Change LAA Closure Decisions?

Strengths and Limitations of VKA and NOACs in Clinical Practice

Pivotal Trial Design Considerations: Noninferiority vs Superiority, Device, Control Arm Anticoagulation Durations, NOAC Considerations and More Industry and Clinician Perspectives

Debate: Is Left Atrial Appendage Closure Underutilized? No, NOACs Have the Best Efficacy and Safety Profile for Most Patients!

Debate #2: Is LAA Closure Preferred First-line Treatment in Patients With Recent Stents or ACS? No A Combination of Antiplatelet Agents and Warfarin/NOACs Shoud Be Tried First!

Meta-analysis and Synthesis of Watchman Trials: Relative Safety and Efficacy vs Warfarin and NOACs in Anticoagulant Indicated Patients (Including Cost-effectiveness)

What are Valid Absolute and Relative Contraindications to Warfarin and NOACs?

Warfarin and NOACS for Atrial Fibrillation: Efficacy, Complications, and Compliance

Bleeding and Stroke Risk Assessment in Atrial Fibrillation: Choosing between Warfarin, NOACS, Antiplatelets, or Nothing?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content